In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.

To combat the threat of many emerging infectious diseases, DNA immunization offers a unique and powerful approach to the production of high-quality monoclonal antibodies (mAbs) against various pathogens. Compared with traditional protein-based immunization approaches, DNA immunization is efficient for testing novel immunogen designs, does not require the production or purification of proteins from a pathogen or the use of recombinant protein technology and is effective at generating mAbs against conformation-sensitive targets. Although significant progress in the use of DNA immunization to generate mAbs has been made over the last two decades, the literature does not contain an updated summary of this experience. The current review provides a comprehensive analysis of the literature, including our own work, describing the use of DNA immunization to produce highly functional mAbs, in particular, those against emerging infectious diseases. Critical factors such as immunogen design, delivery approach, immunization schedule, use of immune modulators and the role of final boost immunization are discussed in detail.
DNA immunization as a technology platform for monoclonal antibody induction

A newly identified betacoronavirus, human coronavirus EMC (HCoV-EMC), has been isolated from several patients with respiratory and renal disease in the Middle East. While only a few infected patients have been identified, the mortality of the infection is greater than 50%. Like its better-known cousin severe acute respiratory syndrome coronavirus (SARS-CoV), HCoV-EMC appears to have originated from bats. In a recent article in mBio, Muller et al. described several important differences between the two viruses [M. A. Muller et al., mBio 3(6):e00515-12, 2012, doi:10.1128/mBio.00515-12]. Unlike SARS-CoV, HCoV-EMC can directly infect bat cells. As important, HCoV-EMC does not enter cells using the SARS-CoV receptor, human angiotensin-converting receptor -2 (hACE2) . These results provide a strong incentive for identifying the host cell receptor used by HCoV-EMC. Identification of the receptor will provide insight into the pathogenesis of pulmonary and renal disease and may also suggest novel therapeutic interventions. Citation Perlman S, Zhao J. 2013. Human coronavirus EMC is not the same as severe acute respiratory syndrome coronavirus. mBio 4(1):e00002-13.
Human Coronavirus EMC Is Not the Same as Severe Acute Respiratory Syndrome Coronavirus

Using 11 overlapping synthetic peptides covering more than 95% of the amino acid sequence of capsid protein of rubella virus, 7 CD4+ T cell clones (Rl 0, Rl 1, R18, A2, Al 0, Al 1, and Al 2) isolated from 2 rubella seropositive donors reacted strongly to rubella capsid peptides C6 (residues 119-l 521, C9 (residues 205-233), or Cl 1 (residues 255-280), respectively, in both proliferation and cytotoxicity assay. Truncated peptides C6E (residues 125-l 39), C9B (residues 205-216), and Cl 1 E (residues 260-272) were shown to be involved directly to the T cell determinants of C6, C9, and Cl 1, respectively. Genetic restriction of these T cell clones was analyzed by using human cell lines with various HLA-DR phenotypes as targets and/or antigen-presenting cells in cytotoxicity assay and/or proliferation assays. The results indicated that the recognition of peptide C6 byT cell clones (Rl 1 and R18) was associated with DRw9 molecule, while the HLA restriction element of the responses of other T cell clones (A2 and Al 1, Al 0, and Al 2) that reacted with peptide C9 or Cl 1 was DR4 molecule. However, there may be a cross-recognition by the T cell clone (Al 2) between DRl and DR4 subtypes.
Characterization of the Specificity and Genetic Restriction of Human CD4+ Cytotoxic T Cell Clones Reactive to Capsid Antigen of Rubella Virus